Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 156 of the 160 references it cites were found in a registry or an index; none of the 220 sources its claims cite is checked for support yet.

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders

Open access
Murphy, Tanya K., Lewin, Adam B., Storch, Eric A., Stock, Saundra · 2013 · Journal of the American Academy of Child & Adolescent Psychiatry

Abstract

Tic disorders, including Tourette's disorder, present with a wide range of symptom severity and associated comorbidity. This Practice Parameter reviews the evidence from research and clinical experience in the evaluation and treatment of pediatric tic disorders. Recommendations are provided for a comprehensive evaluation to include common comorbid disorders and for a hierarchical approach to multimodal interventions.

Overview

CoChat Summary

TL;DR

This AACAP Practice Parameter synthesizes evidence and clinical consensus on assessing and treating pediatric tic disorders, including Tourette’s disorder, emphasizing comprehensive evaluation for comorbidity and hierarchical multimodal care. It recommends psychoeducation, behavioral therapy (HRT/C-BIT), and medication for moderate-to-severe impairment, while not endorsing deep brain stimulation, repetitive transcranial magnetic stimulation, special diets, or dietary supplements.

Key findings

  • Chronic tic disorder (CTD) prevalence is estimated at 0.5% to 3%; approximately 7% of school-age children had tics in the previous year, transient tics approximately 5%, and all tics range from 5.9% to 18% in boys and 2.9% to 11% in girls, with a male preponderance of at least 2:1. Average age of onset is 7 years, peak prevalence/severity is around 9 to 12 years, 65% have remission or marked attenuation by age 18 to 20 years, and 25% have tics into adulthood.
  • Comorbidity is common: 20% to 60% of Tourette’s disorder patients meet criteria for OCD and 20% to 38% of youth with OCD report comorbid tics; ADHD co-occurs in as many as 50% of all childhood CTD cases and 60% to 80% of clinically referred TD cases, with ADHD incidence 7 to 8 times greater than in the general population even in mild CTD. Learning disabilities are approximately 23% in youth with chronic tics; 36% of 200 pediatric TD cases had academic difficulties; among 138 youth with CTD, 46% had school-related problems, with comorbid ADHD symptoms at nearly 4-fold increased risk; 4.6% of youth with TD had comorbid ASD.
  • Behavioral treatment: in a randomized trial comparing habit reversal training (HRT) to attention control in 25 youth, HRT was associated with a 50% response rate, 30% reduction in tic severity, and approximately 50% reduction in tic-related impairment, with 46% classified as responders versus 25% in the control arm. In the multisite C-BIT trial of 126 youth with TD, 52.5% responded to an 8-session, 10-week HRT-based intervention versus 18.5% in the control condition; tic symptom severity reduction was 51% versus 30%, with a between-groups effect size of 0.64.
  • Medication/other: alpha-2 agonists have an effect size of 0.5 for tic amelioration; a meta-analysis found medium-to-large effect (0.68) in trials enrolling subjects with tics and ADHD but only small, nonsignificant benefit (0.15) in trials excluding ADHD. Risperidone was effective in pediatric TD at doses of 1.0 to 3.5 mg/day. Ziprasidone showed a 39% decrease on the YGTSS versus 16% for placebo; atomoxetine resulted in 50% tic reduction versus 33.8% with placebo; metoclopramide resulted in 39% tic reduction versus 13% with placebo; ondansetron had 54% improved versus 21% with placebo. Levetiracetam did not demonstrate significant benefit, and there was no evidence that pramipexole has efficacy in suppressing tics. Deep brain stimulation, repetitive transcranial magnetic stimulation, special diets, and dietary supplements lack empirical support and are not recommended.

Methods

  • Literature search used Medline, PubMed, PsycINFO, and Cochrane Library with terms Tourette’s Disorder, Tourette syndrome, or Tic Disorder, English language, human studies, from January 1, 1965 to March 29, 2013, yielding 3,764 Medline citations, 3,172 PsycINFO citations, and 3 Cochrane reviews. The authors selected 149 publications and 25 RCTs that enrolled pediatric subjects with an effective N of at least 20 (Table 2 reports N > 20).
  • Recommendations are graded as Clinical Standard [CS], Clinical Guideline [CG], Clinical Option [OP], or Not Endorsed [NE], with empirical evidence rated as randomized controlled trial [rct], controlled trial [ct], uncontrolled trial [ut], or case series/report [cs]. The Parameter was reviewed by experts and a Consensus Group and approved by the AACAP Council on July 29, 2013.
  • Main analysis is an evidence synthesis and clinical consensus process producing a hierarchical approach to multimodal assessment and treatment.

Limitations

  • Stated in the paper: AACAP Practice Parameters are developed to assist psychiatric decision making and are not intended to define the sole standard of care; they are not inclusive of all proper methods nor exclusive of other methods, and ultimate judgment for a particular patient must be made by the clinician in light of all circumstances, available options, and resources.
  • Evident from the text: large, multisite, randomized, placebo-controlled trials for pediatric tic disorders are few; many medication studies enrolled primarily adults; most medication treatment studies target moderate to severe tics and result in symptom reduction but not remission; there are no systematic studies comparing HRT to medication or combined therapies in youth.
  • Evident from the text: some areas are understudied, including non-OCD mood/anxiety disorders, explosive/rage symptoms, and complementary/alternative therapies; co-occurrence estimates may be inflated by referral bias because youth with comorbidities may be more likely to seek treatment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.jaac.2013.09.015

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 4 Not valid · 172 Not checked · 21 Own results and interpretations

116 more claims

Create a free account to see all 197 claims and to verify the 218 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • Probably not a substantial claim. 37

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 160 references

Research works printed but not linked: 1

  1. 1998, Practice parameters for the assessment and treatment of children and adolescents with language and learning disorders. AACAP, J Am Acad Child Adolesc Psychiatry, 37, 46S

Cited by

See all 276

Metadata

Authors
Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2013-12
Volume
52
Issue
12
Pages
1341-1359
ISSN
0890-8567 (ISSN-L)
OpenAlex
W2960535177
Cited by
276
References
160
Citations by year
2026: 9 · 2025: 32 · 2024: 17 · 2023: 12 · 2022: 22 · 2021: 29 · 2020: 34 · 2019: 23 · 2018: 23 · 2017: 27 · 2016: 18 · 2015: 20 · 2014: 8 · 2013: 1
FWCI
1.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • American Academy of Child and Adolescent Psychiatry
  • International OCD Foundation
  • University of South Florida
  • Otsuka America Pharmaceutical
  • National Alliance for Research on Schizophrenia and Depression
  • Otsuka America
  • Shire
  • National Institutes of Health (UL1TR000077)
  • Centers for Disease Control and Prevention
  • National Institute of Mental Health
  • National Center for Advancing Translational Sciences
  • Janssen Pharmaceuticals
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Clinical Psychology › Stuttering Research and Treatment
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
Keywords
tic disorders, Tourette syndrome, comorbidities, multimodal therapy, treatment guidelines, clinical evaluation, children and adolescents
MeSH terms
Adolescent, Child, Humans, Tic Disorders, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.